

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業(開曼)控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

VOLUNTARY ANNOUNCEMENT

NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED NEW DRUG APPLICATION APPROVAL FOR LEROCICLIB (GB491)

The announcement is made by Genor Biopharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, the China National Medical Products Administration (the “**NMPA**”) has granted the approval of the new drug applications (“**NDA**”) for Lerociclib (GB491). Lerociclib is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (“**HR+/HER2-**”) locally advanced or metastatic breast cancer in combination with:

- an aromatase inhibitor as initial endocrine-based therapy;
- fulvestrant in patients with disease progression following endocrine therapy.

NMPA’s approval of Lerociclib (GB491) will provide a better treatment option for patients with HR+/HER2 – locally advanced or metastatic breast cancer. It is also a significant milestone of the Company’s development and a successful example of the close cooperation and excellent execution of cross-functional teams. The Board expresses its gratitude to all the patients and researchers who contributed to the successful clinical development of Lerociclib (GB491).

About Lerociclib (GB491)

Lerociclib (GB491) is a novel, highly potent, selective, oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) co-developed by the Group and G1 Therapeutics Inc. for use in combination with endocrine therapy in advanced breast cancer.

By Order of the Board
Genor Biopharma Holdings Limited
Mr. Weng Chengyi
Executive Director and Chief Financial Officer

Hong Kong, 29 May 2025

As at the date of this announcement, the Board comprises seven (7) Directors, namely Mr. Weng Chengyi (Chief Financial Officer) as an executive Director; Dr. Lyu Dong, Mr. Yu Tieming and Mr. Liu Yi as non-executive Directors; and Ms. Cui Bai, Mr. Fung Edwin and Mr. Chen Wen as independent non-executive Directors.